Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Breast 1

Conditions

Leukemia, Myeloid, Acute 69Multiple Myeloma 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Myelodysplastic Syndromes 37Lymphoma 37Leukemia, Lymphocytic, Chronic, B-Cell 37Lymphoma, Non-Hodgkin 33Leukemia 32Recurrence 31Lymphoma, B-Cell 30Melanoma 27Lymphoma, Large B-Cell, Diffuse 22Ovarian Neoplasms 17Lymphoma, Mantle-Cell 17Lymphoma, Follicular 16Hematologic Neoplasms 16Carcinoma, Non-Small-Cell Lung 16Burkitt Lymphoma 16Neoplasms 15Lymphoma, B-Cell, Marginal Zone 13Hodgkin Disease 13Carcinoma, Renal Cell 12Head and Neck Neoplasms 11Neuroblastoma 10Leukemia, Biphenotypic, Acute 10Graft vs Host Disease 10Neoplasms, Plasma Cell 9Neoplasm Metastasis 9Colorectal Neoplasms 9Breast Neoplasms 9

Interventions

trifluridine tipiracil drug combination 1spartalizumab 1selinexor 1ixazomib 1futibatinib 1fludarabine 1atezolizumab 1TAS-116 1Ramucirumab 1Ifosfamide 1Gemcitabine 1Fluorouracil 1Cyclophosphamide 1Cisplatin 1Carboplatin 1Bevacizumab 14-(2-fluoro-4-((((2-phenylacetyl)amino)thioxomethyl)amino)phenoxy)-7-methoxy-N-methyl-6-quinolinecarboxamide 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Sarcoma, Alveolar Soft Part × fludarabine × Clear all
NCT07297667 2026-05-12

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Canadian Cancer Trials Group

Phase 1 Not yet recruiting
30 enrolled
BreastGenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡